

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

# Journal Pre-proof

Non-invasive mechanical ventilation or high-flow oxygen therapy in the COVID-19 pandemic: Dead heat broken

A. González-Castro, V. Modesto i Alapont, A. Medina, A. Fajardo Campoverde



Please cite this article as: { doi: https://doi.org/

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier.



es crp MEDIN 1804 S0210-5691(22)00226-1 10.1016/j.medin.2022.06.005 unknown 2022

### SCIENTIF LETTER

## Non-invasive mechanical ventilation or high-flow oxygen therapy during the COVID-19 pandemic: tie undone

Ventilación mecánica no invasiva u oxigenoterapia de alto flujo en la pandemia de COVID-19: el empate se deshizo

#### Autores:

Alejandro González-Castro (1), Vicente Modesto i Alapont (2), Alberto Medina (3), Aurelio Fajardo Campoverde (4).

1 Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: jandro120475@hotmail.com.

2 Servicio de Pediatría, Unidad de Cuidados Intensivos Pediátricos, Hospital Universitari i Politècnic La Fe, Valencia, Spain..

3 Servicio de Pediatría Unidad de Cuidados Intensivos Pediátricos, Hospital Universitario Central de Asturias, Oviedo, Spain.

4 Medicina Interna, Unidad de Paciente Critico, MsC en Medicina Intensiva, MsC en Ventilación Mecánica, Universitat de Valencia, Grupo de Ventilación Mecánica Chile-Drive Flow Org, Viña del Mar, Chile.

**Centro**: Hospital Universitario Marqués de Valdecilla. Dirección del centro: Avda. Valdecilla s/n; 39008 Santander.

Autor de correspondencia: Dr. Alejandro Gonzalez Castro. Hospital Universitario Marqués de Valdecilla. Secretaria Medicina Intensiva. Pabellón 17, -1. 39008 Santander. Tfno: 942 202520 (ext 73334)Email: e409@humv.es Todos los autores reconocen no presentar conflicto de intereses en la realización del presente trabajo. El presente manuscrito no ha recibido financiación alguna.

### To the Editor,

During the recent COVID-19 pandemic, non-invasive respiratory support has played a crucial role<sup>1</sup> in the management of patients with acute hypoxemic respiratory failure.

The best therapeutic option for these patients has always been a matter of discussion.<sup>2</sup> Compared to traditional CPAP based non-invasive mechanical ventilation or the use of 2 different levels of pressure, oxygen therapy administered through high-flow nasal cannula (HFNC) has been gaining popularity probably due to how easy it is to use, its high tolerability, and the possibility of applying it outside the ICU setting.<sup>3</sup> All these qualities made it an attractive therapeutic option within the first difficult days of the pandemic. However, scientific evidence that backed its use was insufficient.<sup>4</sup> This triggered our former letter where we claimed, at least temporarily, a tie in this match between both non-invasive respiratory supports.

In our own opinion, the evidence generated by the RECOVERY-RS<sup>5</sup> trial has turned the tide in favor of non-invasive mechanical ventilation (NIMV). In sports terminology «tie has been undone at the overtime».

The RECOVERY-RS trial was conducted from April 6, 2020 through May 3, 2021 in 48 hospitals from the United Kingdom and Jersey. Patients were randomized to receive CPAP (N = 380), high-flow nasal oxygen (N = 418) or conventional oxygen therapy (N = 475). To maximize performance given the harsh conditions of the pandemic, the study design is a little special. The study consists of 2 parallel randomized clinical trials that share the same control group: in NIMV only capable hospitals, patients were randomized to receive CPAP or conventional oxygen therapy. In HFNC only capable hospitals, however, patients were randomized to receive HFNC or conventional oxygen therapy. In hospitals with the 3 ventilation systems available, randomization occurred among the 3 groups. Primary endpoint was a composite of orotracheal intubation or 30day mortality. In the 1273 patients studied, the need for orotracheal intubation or 30-day mortality was significantly lower with CPAP (137/377 36.3%) compared to conventional oxygen therapy (158/356 = 44.4%), an absolute difference of -8% (95%CI, - from 15% down to -1%); P = 0.03. However, the difference between HFNC (184/415 = 44.3%) and conventional oxygen therapy (166/368 = 45.1%) was not statistically significant, an absolute difference of -1% (95%CI, from 8% to 6%); P = .83. Due to the randomization-generated comparison and assuming interchangeability between both control groups, Bayesian analysis with the beta-binomial model using a non-informative prior distribution confirmed that the chances of CPAC exceeding HFNC are 0.988 (figure 1) with a number needed to treat of 12.4 patients (95%CI = 6-52) (figure 2).

To improve the quality of our healthcare we can assess the meaning of these results by applying these findings to our own data. To perform this easy analysis, we conducted consecutive sampling of patients included in the registry of patients with COVID-19 from our ICU—after approval by the local research ethics committee and after obtaining

the patients or their legal representatives' informed consent—from March 2020 through March 2022 with the diagnosis of moderate or severe hypoxemic respiratory failure. In 788 (88.14%) out of a total of 894 patients with SARS-CoV-2 infection confirmed the reason for ICU admission was acute hypoxemic respiratory failure. We decided to use HFNC on 477 of these patients (53.4%) in our ICU as a first-line respiratory support therapy. The 30-day mortality rate of these patients was 7.33%, and the composite endpoint of orotracheal intubation or 30-day mortality appeared in 263 patients (55.13%). *Ceteris paribus*, if we had used CPAP instead of HFNC in these 477 patients, we would have had 40 fewer patients (95%CI = 8 to 79) in whom we would have had to use intubation or who would have died otherwise.

With the knowledge generated by the RECOVERY-RS trial, tie has been definitively undone. The abuse of HFNC and the lack of rigorous management—based on the scientific evidence available—of non-invasive ventilatory support devices will lead HFNC to dying from its own success without any benefits for the patients whatsoever.

## Funding

None whatsoever.

## **Conflicts of interest**

None reported.

Conflict of Interest and Authorship Conformation For Please check the following as appropriate:

o All authors have participated in (a) conception and design, or analysis and interpretation of the data; (b) drafting the article or revising it critically for important intellectual content; and (c) approval of the final version.

o This manuscript has not been submitted to, nor is under review at, another journal or other publishing venue.

o The authors have no affiliation with any organization with a direct or indirect financial interest in the subject matter discussed in the manuscript

o The following authors have affiliations with organizations with direct or indirect financial interest in the subject matter discussed in the manuscript:

References

Bibliografía:

<sup>1</sup> Cinesi Gómez C., Peñuelas Rodríguez Ó., Luján Torné M., Egea Santaolalla C., Masa Jiménez J.F., García Fernández J. Clinical consensus recommendations regarding non-

# Journal Pre-proof

invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. Med Intensiva. 2020 S0210-5691(20)30094-2. http://doi:10.1016/j.medin.2020.03.005

<sup>2</sup> González-Castro A, Fajardo Campoverde A, Medina A, Alapont VMI. Non-invasive mechanical ventilation and high-flow oxygen therapy in the COVID-19 pandemic: the value of a draw. Med Intensiva (Engl Ed). 2021; 45: 320-321. https://doi:10.1016/j.medin.2020.04.017

<sup>3</sup> Ricard J-D, Roca O, Lemiale V, Corley A, Braunlich J, Jones P, et al. Use of nasal high flow oxygen during acute respiratory failure. Intensive Care Med 2020; 46: 2238-2247.


<sup>4</sup> Crimi C, Pierucci P, Renda T, Pisani L, Carlucci A. High-Flow Nasal Cannula and COVID-19: A Clinical Review. Respir Care. 2022; 67: 227-240 https://doi:10.4187/respcare.09056


<sup>5</sup> Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Baillie JK, et al; RECOVERY-RS Collaborators. Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA. 2022; 327: 546-558. https://doi:10.1001/jama.2022.0028

# **Journal Pre-proof**

**Figura 1**: Análisis bayesiano con el modelo Beta-Binomial utilizando una distribución a priori no informativa.

Pie de Figura: el análisis bayesiano con el modelo Beta-Binomial utilizando una distribución a priori no informativa nos indica que la probabilidad de que la CPAP sea superior a las CNAF es de 0,988.





Contractor Internet and Authorship Contention Form

Planes chart the full second as appropriate

- $0\quad Am anythese basis participants in (a) encomption and dampt, or analysis and compressions of the damp, (b) deathing the encoders or postering a schemely for important intelligitud constant, and (c) approach of the light variant.$
- 8 This measurement has our base automation to, nor to under on-one of, another payment or other publications versus.
- C The addition have no affiliation with any engineering with a direct or reduced forestill interact in the addition matter discussed in the manufactor.

 The Patheming extense have attitudient with regaritances provide down or torteast framework research in the subject means of downward in the mean array of Authors's same. Authors's same. Magnetic formation Cancer. Minimum Meansare at Verstatistic Sciences, Seen. Theremuse attended Minimum Meansare at Verstatistic Sciences, Seen. Theremuse attended to Constanting Minimum Meansare attended to Science and Pathemine, United to Constanting Minimum Meansare attended Minimum Meansare attended Minimum Meansare attended Minimum Meansare, Minimum Cancer attended to Constanting Minimum Meansare, Minimum Meansare, Constanting Mini **Figure 1.** Bayesian analysis with the beta-binomial model using non-informative prior distribution. Bayesian analysis with the beta-binomial model using non-informative prior distribution tells us that the chances of CPAP exceeding HFNC are 0.988. gr1

Figure 2. Number needed to treat (NNT). gr2

# TRADUCCIÓN DE FIGURAS

(Color negro: español · Color azul: inglés)

### <u>Figura 1</u>

Diferencia de riesgo Risk difference Densidad de probabilidad p(x) Likelihood density function P(x)

### <u>Figura 2</u>

Número necesario de pacientes a tratar Number needed to treat Densidad de probabilidad p(x)Likelihood density function P(x)(95% Cred Int = 6 to 57) (95% CI, 6 to 57)